At Underdog Pharmaceuticals, Inc. (Underdog), our mission is to cure age-related disease by addressing and repairing the underlying damage driving such disease, and we intend to start with the first true diseasemodifying treatment for atherosclerosis. Our core platform emerged from the research laboratories of SENS Research Foundation (SRF), the only non-profit dedicated to the development … Continue reading Underdog Pharmaceuticals
Seismic Bio, Inc. is an emerging preclinical-stage biopharmaceutical company developing bispecific therapeutic antibodies that enable controlled activation of the immune system to fight cancer. The company is committed to advancing the field of immuno-oncology, with a focus on treating solid tumor types that fail to respond to immune checkpoint inhibitors. Using cutting-edge science at the … Continue reading Seismic Bio
Sardona Therapeutics is scaling new peaks in cancer therapy. We are developing novel small molecule drugs to transform patient outcomes by targeting RNA regulators.
Navega Therapeutics is a preclinical stage company pursuing a radically different approach to treat chronic pain and tackle the opioid epidemic. At Navega, we have developed a novel gene therapy to treat severe chronic pain that is non-addictive, highly specific, and long lasting. We were inspired by nature: there are humans that have a mutation … Continue reading Navega Therapeutics
Matrubials, Inc. is developing novel mammalian milk-protein derived peptides for treatment of severe bacterial infections. Our portfolio includes antibacterial peptides from a natural food source for the newborn, milk, which offers a safety dossier defined by lactation. In comparison to currently available antibiotics and newer candidates being developed by our competitors, our therapeutics are rapidly … Continue reading Matrubials
Epilepsy affects 70M people worldwide including 3.4M people in the US with costs > $15B USD, $1B in EEG costs alone. Detecting and responding to seizures is critical to managing epilepsy. However, > 50% of seizures are unreported because they are difficult to detect and/or not remembered by the person with epilepsy. Eysz is a … Continue reading Eysz
COPD affects 10% of the world’s population and is the third leading cause of death. In the U.S., COPD kills one person every four minutes. The economic burden is high: COPD costs nearly $72B a year, 40% spent on ER and hospital stays. Disease exacerbations (acute lung-function deterioration) account for most hospitalizations; half of patients … Continue reading Respiralabs
NeuScience is a therapeutics company leveraging AI and translational biology to target solid tumor cancers. Our drug discovery platform combines panels of patient-derived tumor cells with machine vision and deep learning to find treatments that target aggressive subpopulations at the single-cell level. We have developed a novel method to learn whole-cell phenotypic biomarkers with detection … Continue reading Neuscience
At ARIZ Precision Medicine, we target epigenetic changes that occur early in cancerization with siRNA-based therapeutics delivered directly to tumor cells. This combination of drug payload and drug delivery system allows for “Dual Targeting” of the cancer cell results in a product that is very safe and potentially curable for the patient.